REVB (Revelation Biosciences) ROCE %: -106.60% (As of Mar. 2026)


REVB Revelation Biosciences Inc REVB
28 GF Score
Price $0.98
! 1 Warning Sign
View Full Analysis

What is Revelation Biosciences ROCE %?

Revelation Biosciences REVB +3.16% 28 ROCE % is -106.60% as of Mar. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Revelation Biosciences's annualized ROCE % for the quarter that ended in Mar. 2026 was -106.60%.

Revelation Biosciences  (NAS:REVB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Revelation Biosciences ROCE % Related Terms

Revelation Biosciences ROCE % Historical Data

* Premium members only.

The historical data trend for Revelation Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences ROCE % Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -721.84 -2,282.56 -224.86 -140.45 -126.93

Revelation Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -220.88 -293.59 -104.84 -99.95 -106.60
REVB
28GF Score
Revelation Biosciences Inc REVB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revelation Biosciences ROCE % Calculation

Revelation Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-9.071/( ( (6.622 - 1.914) + (11.583 - 1.998) )/ 2 )
=-9.071/( (4.708+9.585)/ 2 )
=-9.071/7.1465
=-126.93 %

Revelation Biosciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-12.372/( ( (11.583 - 1.998) + (15.044 - 1.417) )/ 2 )
=-12.372/( ( 9.585 + 13.627 )/ 2 )
=-12.372/11.606
=-106.60 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -106.60% mean?
Revelation Biosciences (REVB) has a ROCE % of -106.60% as of Mar. 2026.
Is Revelation Biosciences' ROCE % too high?
Revelation Biosciences' current ROCE % is -106.60%. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' ROCE % compare to ITRMF and ENSC?
Revelation Biosciences' ROCE % of -106.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Revelation Biosciences's current ROCE % is -106.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current ROCE % of -106.60%. The current ROCE % is -106.60%. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current ROCE % is -106.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revelation Biosciences Business Description

Address 4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score

Get the complete analysis for REVB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.98
Price